is progression-free survival meaningful?
Published 10 years ago • 1.6K plays • Length 3:25Download video MP4
Download video MP3
Similar videos
-
7:53
improved progression-free survival with iressa as adjuvant therapy
-
1:59:57
grace - global resource for advancing cancer education live stream
-
6:56
2020 ttf rare mutations qa panel why mutations have different progression-free survival averages
-
7:54
keytruda combined with anti-vegf treatment:use in patients with advanced nsclc-asco lung review 2022
-
2:22:00
onctalk 2022 -- on demand full video
-
4:19
what is pfs2 in advanced nsclc, and should we care? unique analysis of the keynote-024 trial
-
3:25
are there significant differences among the 1st and 2nd generation egfr tkis?
-
2:01
should we use dna or rna for ngs? - 2022 program: targeted therapies forum
-
36:41
gracecast-053_lung-cancer_socinski on advanced nsclc maintenance therapy
-
5:20
asco lung cancer highlights, pt 11: nintedanib with second line chemotherapy
-
4:08
is there a place for maintenance therapy in extensive stage sclc?
-
12:58
egfr inhibitor therapy in second line
-
23:32
gracecast-077_lung-cancer_asco 2011 highlights - advanced/metastatic nsclc
-
11:58
asco lung cancer roundtable - mesothelioma updates
-
33:47
gracecast-049_lung-cancer_weiss on egfr therapy for early stage nsclc
-
6:40:28
full video ondemand -targeted therapies patient forum 2022 - for those living with lung cancer
-
3:53:33
targeted therapies in lung cancer patient forum 2017, cleveland ohio - main morning sessions
-
3:28
should third generation egfr inhibitors be used before or after progression?
-
5:11
gracecast-114_lung-cancer_asco 2012 lc highlights: dr. neal on mek inhibitor selumetinib in nsclc